Literature DB >> 19176532

Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.

Maxwell Afari Gyamfi1, Yu-Jui Yvonne Wan.   

Abstract

Peroxisome proliferators, such as the lipid-lowering fibrates that function as agonists for peroxisome proliferator-activated receptor alpha (PPARalpha), induce liver tumors in rodents and may produce cholestasis in humans. Considerable attention has focused on peroxisome proliferator-induced hepatocellular carcinoma, a phenomenon not noted in man, whereas limited studies examine fibrates and other therapeutic drugs that induce cholestasis, a common finding in humans. Moreover, the mechanisms by which fibrates induce hepatocyte proliferation and cholestasis are still not fully understood. We have examined the role of hepatocyte retinoid X receptor alpha (RXRalpha), an essential partner of PPARalpha, in modulating WY-14,643-induced hepatocyte proliferation and cholestasis. WY-14,643 treatment induced hepatomegaly in wild type (WT) mice that was also accompanied by induction of the expression of cyclins D1, D3, A2, and B1 and Cdc2 as well as inhibition of Wee 1. Such changes were either absent or greatly reduced in hepatocyte RXRalpha-null mice. Furthermore, neither WY-14,643 treatment nor RXRalpha deficiency affected apoptosis, indicating the importance of PPARalpha/RXRalpha in regulating Wee 1-mediated Cdc2/cyclin B1 expression for cells to enter into mitosis. WY-14,643 treatment also induced cholestasis and liver injury, which is evidenced by induction of alanine aminotransferase, alkaline phosphatase, and hepatic bile acid levels in WT mice. Hepatocyte RXRalpha deficiency protected the mice from WY-14,643-induced liver injury. WY-14,643-mediated induction of the small heterodimer partner, Mrp3, and Cyp3a11 levels was greater in hepatocyte RXRalpha-null than in WT mouse livers suggesting enhanced repression of bile acid synthesis and increased efflux of bile acids into blood for renal excretion as well as hydroxylation of bile acids because of hepatocyte RXRalpha deficiency. These data establish a crucial role of hepatocyte RXRalpha in regulating WY-14,643-mediated cell cycle progression as well as bile acid homeostasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19176532      PMCID: PMC2666584          DOI: 10.1074/jbc.M808861200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice.

Authors:  J M Peters; N Hennuyer; B Staels; J C Fruchart; C Fievet; F J Gonzalez; J Auwerx
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

2.  Fenofibrate-induced liver injury.

Authors:  Kazufumi Dohmen; Chun Yang Wen; Shinya Nagaoka; Koji Yano; Seigo Abiru; Toshihito Ueki; Atsumasa Komori; Manabu Daikoku; Hiroshi Yatsuhashi; Hiromi Ishibashi
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids.

Authors:  Hanns-Ulrich Marschall; Martin Wagner; Karl Bodin; Gernot Zollner; Peter Fickert; Judith Gumhold; Dagmar Silbert; Andrea Fuchsbichler; Jan Sjövall; Michael Trauner
Journal:  J Lipid Res       Date:  2005-12-04       Impact factor: 5.922

4.  Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report.

Authors:  M Isabel Lucena; Raúl J Andrade; Luis Vicioso; F Jesús González; Ketevan Pachkoria; Beatriz García-Muñoz
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

Review 5.  Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

Authors:  Jeffrey M Peters; Connie Cheung; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-06-23       Impact factor: 4.599

6.  Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis.

Authors:  S Teng; M Piquette-Miller
Journal:  Br J Pharmacol       Date:  2007-04-16       Impact factor: 8.739

7.  Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.

Authors:  Gernot Zollner; Martin Wagner; Tarek Moustafa; Peter Fickert; Dagmar Silbert; Judith Gumhold; Andrea Fuchsbichler; Emina Halilbasic; Helmut Denk; Hanns-Ulrich Marschall; Michael Trauner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-12-15       Impact factor: 4.052

8.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.

Authors:  J M Peters; R C Cattley; F J Gonzalez
Journal:  Carcinogenesis       Date:  1997-11       Impact factor: 4.944

Review 9.  Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.

Authors:  Andreas Geier; Martin Wagner; Christoph G Dietrich; Michael Trauner
Journal:  Biochim Biophys Acta       Date:  2006-05-17

10.  Hepatocyte retinoid X receptor alpha-dependent regulation of lipid homeostasis and inflammatory cytokine expression contributes to alcohol-induced liver injury.

Authors:  Maxwell Afari Gyamfi; Lin He; Samuel William French; Ivan Damjanov; Yu-Jui Yvonne Wan
Journal:  J Pharmacol Exp Ther       Date:  2007-11-01       Impact factor: 4.030

View more
  10 in total

1.  Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells.

Authors:  Chad N Brocker; Jiang Yue; Donghwan Kim; Aijuan Qu; Jessica A Bonzo; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-01-12       Impact factor: 4.052

2.  Retinoic Acid-mediated Nuclear Receptor Activation and Hepatocyte Proliferation.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  J Exp Clin Med       Date:  2009-12

3.  Impaired bile acid handling and aggravated liver injury in mice expressing a hepatocyte-specific RXRα variant lacking the DNA-binding domain.

Authors:  Astrid Kosters; Julio C Felix; Moreshwar S Desai; Saul J Karpen
Journal:  J Hepatol       Date:  2013-10-10       Impact factor: 25.083

Review 4.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 5.  Pathogenesis of alcoholic liver disease: the role of nuclear receptors.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2010-05

6.  Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.

Authors:  Dipanjan Chanda; Chul Ho Lee; Yong-Hoon Kim; Jung-Ran Noh; Don-Kyu Kim; Ji-Hoon Park; Jung Hwan Hwang; Mi-Ran Lee; Kyeong-Hoon Jeong; In-Kyu Lee; Gi Ryang Kweon; Minho Shong; Goo-Taeg Oh; John Y L Chiang; Hueng-Sik Choi
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

7.  Deregulation of growth factor, circadian clock, and cell cycle signaling in regenerating hepatocyte RXRalpha-deficient mouse livers.

Authors:  Xiaoxia Yang; Minglei Guo; Yu-Jui Yvonne Wan
Journal:  Am J Pathol       Date:  2009-12-24       Impact factor: 4.307

8.  PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis.

Authors:  Xueyan Zhou; Lijuan Cao; Changtao Jiang; Yang Xie; Xuefang Cheng; Kristopher W Krausz; Yunpeng Qi; Lu Sun; Yatrik M Shah; Frank J Gonzalez; Guangji Wang; Haiping Hao
Journal:  Nat Commun       Date:  2014-09-03       Impact factor: 14.919

Review 9.  PPARα: A potential therapeutic target of cholestasis.

Authors:  Xiaoyin Ye; Tong Zhang; Han Han
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

10.  On the Role of Illness Duration and Nutrient Restriction in Cholestatic Alterations that Occur During Critical Illness.

Authors:  Marc Jenniskens; Fabian Güiza; Marlies Oorts; Sarah Vander Perre; Sarah Derde; Thomas Dufour; Steven Thiessen; Pieter Annaert; Greet Van den Berghe; Lies Langouche
Journal:  Shock       Date:  2018-08       Impact factor: 3.454

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.